Modular building startup Boxabl to list on Nasdaq in $3.5 billion SPAC deal
Modular housing is widely recognized for its potential to deliver affordable, timely, and scalable housing solutions in both emergency and market-driven contexts.
Innovation in the housing market – a segment of the economy most sensitive to monetary policy – is also necessitated by rising housing prices, which hit a record high in June amid elevated interest rates and supply crunch.
The deal will allow Boxabl to expand its production capabilities and meet growing demand for its modular building systems, as well as invest in research and development.
Founded in 2017, Las Vegas-based Boxabl designs and manufactures foldable, modular homes. Known for its foldable 361 square foot "Casita" homes, some of the company's housing models can be purchased for as little as $19,999.
Boxabl is led by founders and co-CEOs Paolo and Galiano Tiramani. FG Merger will issue 350 million shares to Boxabl.
SPACs, also known as blank-check firms, raise capital through an initial public offering with the sole purpose of taking a private company public.
Listing shares via SPAC mergers allows companies to avoid some scrutiny that comes with the traditional IPO process.
Boxabl, which has raised over $230 million to date, has previously also used crowdfunding to raise capital, an alternative fundraising strategy that allows small everyday investors to buy shares in a company.
The company also adopted a bitcoin treasury strategy in May, allowing for a percentage of its assets to acquire the cryptocurrency.
The combined company will be listed on the Nasdaq under the symbol "BXBL."
Maxim Group and Winston & Strawn advised Boxabl, while Loeb & Loeb advised FG Merger.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
21 minutes ago
- Reuters
Schrödinger stops development of blood cancer therapy after two patient deaths
Aug 14 (Reuters) - Schrödinger (SDGR.O), opens new tab said on Thursday it has stopped the development of an experimental drug after the death of two patients with a type of blood cancer in an early-stage trial, sending its shares down nearly 17% before the bell. The company was testing the therapy, SGR-2921, in patients with high-risk myelodysplastic syndromes, a group of blood cancers in which the bone marrow doesn't produce enough healthy blood cells, and its more serious form - acute myeloid leukemia. The drug was considered to have contributed to the deaths of two AML patients in the trial, the company said. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients," Chief Medical Officer Margaret Dugan said. In pre-clinical trial, the therapy showed responses against the cancer, which suggested SGR-2921 could ultimately be used in combination with standard of care treatments, the company said. The experimental drug was designed to work by blocking CDC7, a protein that helps cancer cells repair DNA damage during replication. By inhibiting this protein, the drug causes cancer cells to accumulate fatal levels of DNA damage.
Reuters
22 minutes ago
- Reuters
Ulta Beauty and Target plan to conclude partnership in 2026
Aug 14 (Reuters) - Ulta Beauty (ULTA.O), opens new tab and Target (TGT.N), opens new tab on Thursday said they have mutually agreed not to renew their shop-in-shop partnership when the current agreement concludes in August 2026.
Reuters
22 minutes ago
- Reuters
Citgo Petroleum returned to profit in the second quarter
HOUSTON, Aug 14 (Reuters) - Venezuela-owned U.S. refiner Citgo Petroleum registered net income of $100 million in the second quarter versus a $25 million loss in the same quarter last year, finishing the period with liquidity of $2.6 billion, it said on Thursday. The Houston-based refiner had recorded losses in two consecutive quarters of loss amid weak margins before its second-quarter results. Its parent company PDV Holding is being auctioned by a U.S. court to pay creditors for past debt defaults and expropriations in Venezuela. Between April and June, the seventh-largest U.S. refiner increased its total processing to an average of 858,000 barrels per day from 833,000 bpd in the first quarter, registering a crude utilization rate of 101%. "Reliable operations in a more supportive market environment" led to a stronger second quarter, the company said in a release. In the second half of the year, Citgo plans to advance key projects, but it rescheduled some turnaround activities at its Lemont, Illinois and Lake Charles, Louisiana refineries to next year, it added. As a consequence, projected turnaround, catalyst and capital expenditures for this year were reduced from approximately $960 million to some $696 million. Citgo's marketing sales volume was 431,000 bpd in the quarter, up slightly from the previous period.
